Pfizer Inc
PFE26.430USD
+0.580+2.24%
종가 12/15, 16:00（ET）시세는 15분 지연됩니다
150.28B시가총액
15.28P/E TTM
자세한 내용은 Pfizer Inc 회사
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Pfizer Inc 정보
종목 코드 PFE
회사 이름Pfizer Inc
상장일Feb 22, 2080
CEOBourla (Albert)
직원 수81000
유형Ordinary Share
회계 연도 종료Feb 22
주소66 Hudson Boulevard East
도시NEW YORK
증권 거래소NASDAQ OMX NASDAQ Basic NYSE
국가United States of America
우편 번호10001-2192
전화12127332323
웹사이트https://www.pfizer.com/
종목 코드 PFE
상장일Feb 22, 2080
CEOBourla (Albert)
Pfizer Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
Mr. Aamir Malik
Mr. Aamir Malik
Executive Vice President, Chief US Commercial Officer
Executive Vice President, Chief US Commercial Officer
29.55K
+7800.53%
Ms. Payal Sahni
Ms. Payal Sahni
Executive Vice President, Chief People Experience Officer
Executive Vice President, Chief People Experience Officer
24.85K
+6.62%
Mr. Cyrus Taraporevala
Mr. Cyrus Taraporevala
Independent Director
Independent Director
10.00K
--
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
10.00K
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
수익 분석
통화: USD마지막 업데이트: Mon, Oct 6
통화: USD마지막 업데이트: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
사업별USD
이름
수익
비율
Eliquis alliance revenues and direct sales
2.00B
13.67%
Vyndaqel family
1.61B
11.02%
Prevnar family
1.38B
9.44%
All other Hospital
1.09B
7.42%
Oncology-Ibrance
1.05B
7.16%
기타
7.52B
51.29%
지역별USD
이름
수익
비율
United States
8.89B
60.70%
Developed Markets
3.39B
23.16%
Emerging Markets
2.37B
16.15%
사업별
지역별
사업별USD
이름
수익
비율
Eliquis alliance revenues and direct sales
2.00B
13.67%
Vyndaqel family
1.61B
11.02%
Prevnar family
1.38B
9.44%
All other Hospital
1.09B
7.42%
Oncology-Ibrance
1.05B
7.16%
기타
7.52B
51.29%
주식 보유 통계
마지막 업데이트: Sun, Nov 16
마지막 업데이트: Sun, Nov 16
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
9.35%
State Street Investment Management (US)
5.26%
BlackRock Institutional Trust Company, N.A.
5.17%
Geode Capital Management, L.L.C.
2.27%
Norges Bank Investment Management (NBIM)
1.65%
기타
76.30%
주주
주주
비율
The Vanguard Group, Inc.
9.35%
State Street Investment Management (US)
5.26%
BlackRock Institutional Trust Company, N.A.
5.17%
Geode Capital Management, L.L.C.
2.27%
Norges Bank Investment Management (NBIM)
1.65%
기타
76.30%
주주 유형
주주
비율
Investment Advisor
33.35%
Investment Advisor/Hedge Fund
23.13%
Research Firm
2.99%
Pension Fund
2.47%
Bank and Trust
1.76%
Sovereign Wealth Fund
1.72%
Insurance Company
1.27%
Hedge Fund
0.93%
Holding Company
0.05%
기타
32.34%
기관 주식 보유
마지막 업데이트: Wed, Oct 1
마지막 업데이트: Wed, Oct 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q3
4830
3.80B
66.84%
-140.11M
2025Q2
4945
3.85B
67.75%
-89.09M
2025Q1
5074
3.86B
67.90%
-51.97M
2024Q4
5153
3.84B
67.74%
-83.26M
2024Q3
5005
3.85B
67.99%
-51.77M
2024Q2
5026
3.84B
67.75%
-120.77M
2024Q1
5032
3.89B
68.71%
-120.39M
2023Q4
5089
3.97B
70.25%
-96.67M
2023Q3
4952
4.00B
70.89%
-71.80M
2023Q2
4962
4.02B
71.16%
-62.35M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
530.68M
9.33%
+10.10M
+1.94%
Jun 30, 2025
State Street Investment Management (US)
296.30M
5.21%
-669.22K
-0.23%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
288.89M
5.08%
-2.65M
-0.91%
Jun 30, 2025
Geode Capital Management, L.L.C.
127.47M
2.24%
+1.82M
+1.45%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
93.65M
1.65%
+5.87M
+6.68%
Jun 30, 2025
Wellington Management Company, LLP
77.00M
1.35%
-26.49M
-25.60%
Jun 30, 2025
State Farm Insurance Companies
57.59M
1.01%
-158.70K
-0.27%
Jun 30, 2025
MFS Investment Management
72.76M
1.28%
-276.04K
-0.38%
Jun 30, 2025
BlackRock Asset Management Ireland Limited
54.65M
0.96%
+4.18M
+8.29%
Jun 30, 2025
BlackRock Investment Management (UK) Ltd.
48.87M
0.86%
+8.45M
+20.91%
Jun 30, 2025
더 보기
관련 ETF
마지막 업데이트: Mon, Dec 1
마지막 업데이트: Mon, Dec 1
이름
비율
VanEck Pharmaceutical ETF
10.43%
First Trust NASDAQ Pharmaceuticals ETF
7.73%
Franklin US Dividend Booster Index ETF
7.39%
First Trust Morningstar Dividend Leaders Index Fund
6.54%
WBI Power Factor High Dividend ETF
4.87%
Invesco Pharmaceuticals ETF
4.84%
Coastal Compass 100 ETF
4.8%
iShares U.S. Pharmaceuticals ETF
4.43%
Amplify Weight Loss Drug & Treatment ETF
4.14%
Roundhill GLP-1 & Weight Loss ETF
3.73%
더 보기
VanEck Pharmaceutical ETF
비율10.43%
First Trust NASDAQ Pharmaceuticals ETF
비율7.73%
Franklin US Dividend Booster Index ETF
비율7.39%
First Trust Morningstar Dividend Leaders Index Fund
비율6.54%
WBI Power Factor High Dividend ETF
비율4.87%
Invesco Pharmaceuticals ETF
비율4.84%
Coastal Compass 100 ETF
비율4.8%
iShares U.S. Pharmaceuticals ETF
비율4.43%
Amplify Weight Loss Drug & Treatment ETF
비율4.14%
Roundhill GLP-1 & Weight Loss ETF
비율3.73%
주식 배당금
지난 5년 동안 총
44.91B
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
Oct 09, 2025
PFE.NB Final Cash Dividend of gross USD 0.43 paid on Dec 01, 2025 going ex on Nov 07, 2025
Nov 07, 2025
Dec 01, 2025
Nov 07, 2025
Jun 25, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Sep 02, 2025 going ex on Jul 25, 2025
Jul 25, 2025
Sep 02, 2025
Jul 25, 2025
Apr 23, 2025
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Jun 13, 2025 going ex on May 09, 2025
May 09, 2025
Jun 13, 2025
May 09, 2025
Dec 12, 2024
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025
Jan 24, 2025
Mar 07, 2025
Jan 24, 2025
Oct 09, 2024
PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024
Nov 08, 2024
Dec 02, 2024
Nov 08, 2024
Jun 26, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024
Jul 26, 2024
Sep 03, 2024
Jul 26, 2024
Apr 24, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024
May 10, 2024
Jun 14, 2024
May 09, 2024
Dec 14, 2023
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024
Jan 26, 2024
Mar 01, 2024
Jan 25, 2024
Oct 04, 2023
PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Dec 04, 2023
Nov 09, 2023
Jun 22, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Sep 05, 2023 going ex on Jul 27, 2023
Jul 28, 2023
Sep 05, 2023
Jul 27, 2023
더 보기
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
자주 묻는 질문
Pfizer Inc의 상위 5대 주주는 누구인가요?
Pfizer Inc의 상위 5대 주주는 다음과 같습니다:
The Vanguard Group, Inc.는 530.68M주의 주식을 보유하고 있으며, 전체 주식의 9.33%를 차지합니다.
State Street Investment Management (US)는 296.30M주의 주식을 보유하고 있으며, 전체 주식의 5.21%를 차지합니다.
BlackRock Institutional Trust Company, N.A.는 288.89M주의 주식을 보유하고 있으며, 전체 주식의 5.08%를 차지합니다.
Geode Capital Management, L.L.C.는 127.47M주의 주식을 보유하고 있으며, 전체 주식의 2.24%를 차지합니다.
Norges Bank Investment Management (NBIM)는 93.65M주의 주식을 보유하고 있으며, 전체 주식의 1.65%를 차지합니다.
The Vanguard Group, Inc.는 530.68M주의 주식을 보유하고 있으며, 전체 주식의 9.33%를 차지합니다.
State Street Investment Management (US)는 296.30M주의 주식을 보유하고 있으며, 전체 주식의 5.21%를 차지합니다.
BlackRock Institutional Trust Company, N.A.는 288.89M주의 주식을 보유하고 있으며, 전체 주식의 5.08%를 차지합니다.
Geode Capital Management, L.L.C.는 127.47M주의 주식을 보유하고 있으며, 전체 주식의 2.24%를 차지합니다.
Norges Bank Investment Management (NBIM)는 93.65M주의 주식을 보유하고 있으며, 전체 주식의 1.65%를 차지합니다.
Pfizer Inc의 상위 3대 주주 유형은 무엇인가요?
Pfizer Inc의 주요 주주 유형 상위 3가지는
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.입니다.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.입니다.
Pfizer Inc(PFE)의 주식을 보유한 기관은 몇 개입니까?
2025Q3 기준으로, Pfizer Inc의 주식을 보유한 기관은 총 4830곳이며, 이들이 보유한 주식의 총 가치는 약 3.80B로 전체 발행 주식의 66.84%를 차지합니다. 이는 2025Q2 대비 -0.91% 증가한 수치입니다.
Pfizer Inc의 최대 수익원은 무엇인가요?
FY2025Q2 기준, Pfizer Inc의 Eliquis alliance revenues and direct sales 부문이 가장 높은 매출을 기록했으며, 금액은 2.00B로 전체 매출의 13.67%를 차지했습니다.
